About the Cardiovascular Molecular and Therapeutics Translational Research Group
Heart Disease

About the Cardiovascular Molecular and Therapeutics Translational Research Group

The Cardiovascular Molecular and Therapeutics Translational Research Group aims to increase understanding of molecular mechanisms of advanced heart failure in order to discover new medicines to treat and improve quality of life for patients with this condition.

Easing the Burden of Heart Failure

The prevalence of heart failure is increasing worldwide, increasing the burden on our hospitals, clinicians, communities and families.

Despite best-available treatment options, patients still have a very poor survival rate.

The research by this group is vital to reduce the burden of patients with heart failure and to provide significantly better outcomes for patients.

Highlights for the research group in 2022

In 2022, the group, which has more than nine members, undertook projects that focused on preventing deadly ventricular arrhythmias in heart failure patients. These included the ‘Antiarrhythmic effect of phenytoin in human failing hearts’ study.

Through this research, the group established that phenytoin is able to effectively prevent arrhythmias in a human ventricular model of arrhythmia, using tissue samples from patients with heart failure.

The research group found that it works effectively to prevent arrhythmias in human heart samples from patients who were not receiving Beta-blockers, also spelled β-blockers, (a kind of medicine that slows down a person’s heart activity) at the time of heart transplantation. This is an important result towards providing an additional medicine in this group of patients.

Using phenytoin as a template medicine, the group then designed and synthesised novel compounds. Remarkably, early attempts found some to be more effective than phenytoin at preventing arrhythmias.

At the same time, the group’s ‘Redesigning and optimizing Beta-blocker treatment for patients with heart failure patients’ project, used pharmacological criteria to re-design Beta-blocker use to enable more patients – including those who were previously unable to tolerate Beta-blocker therapy – to take advantage of treatment.

In 2022, the group was also delighted to appoint Dr Kafa Walweel to the group to provide strategic expertise to develop novel antiarrhythmic medicines for patients with heart failure.

Published: November 14, 2023

Related news & events

Fidget blankets handcrafted for patients with dementia at The Prince Charles Hospital

Ageing

Fidget blankets handcrafted for patients with dementia at The Prince Charles Hospital

A group of sewers from the Coolangatta Seniors, known as the “Fabric Floozies,” have handcrafted fidget blankets for patients with dementia at The Prince Charles Hospital.

Find out more

Dementia Action Week 2025: ‘Nobody can do it alone’

Ageing

Dementia Action Week 2025: ‘Nobody can do it alone’

This Dementia Action Week 2025, Dementia Australia wants to encourage people in the community to reach out to people impacted by dementia.

Find out more

Child Life Therapy program expands thanks to Foundation supporters

The Common Good

Child Life Therapy program expands thanks to Foundation supporters

We have been able to fund the expansion of the Child Life Therapy program at The Prince Charles Hospital and into Caboolture Hospital thanks to our remarkable supporters.

Find out more

Dozens cycle for transplant research at 2025 Cycle of Giving

The Common Good

Dozens cycle for transplant research at 2025 Cycle of Giving

The Cycle of Giving has returned to the Sunshine Coast in 2025, with dozens of riders pedalling for vital transplant research.

Find out more

Collaborative Seed Grants at The Prince Charles Hospital

Research Grants

Collaborative Seed Grants at The Prince Charles Hospital

If you’re waiting for the Strawberry Sundae Kisses beer to hit your lips, we’ve got good news! The creation for a good cause is back in 2023, and brewing is…

Find out more

Stone & Wood’s Strawberry Sundae Kisses beer is back in 2025

Uncategorised

Stone & Wood’s Strawberry Sundae Kisses beer is back in 2025

If you’re waiting for the Strawberry Sundae Kisses beer to hit your lips, we’ve got good news! The creation for a good cause is back in 2023, and brewing is…

Find out more

Acknowledging our Corporate Volunteers this National Volunteer Week

Volunteering

Acknowledging our Corporate Volunteers this National Volunteer Week

This National Volunteer Week, we want to say a big thank you to our corporate volunteers who answer our call for help.

Find out more

National Volunteer Week Australia 2025: 'Connecting Communities'

Volunteering

National Volunteer Week Australia 2025: 'Connecting Communities'

National Volunteer Week 2025: Meet the incredible people who give their time and skills through The Prince Charles Hospital Foundation.

Find out more

It's Heart Week: Let’s Talk About the Health of Your Heart

Heart Disease

It's Heart Week: Let’s Talk About the Health of Your Heart

Discover how The Common Good is supporting world-leading heart health research at The Prince Charles Hospital this Heart Week.

Find out more